Replies to post #94508 on Biotech Values

[mcbio]

Re: GILD HCV Update

GILD HCV Update from 1Q10 CC

• GILD has three HCV drugs in phase-1 trials that they will not discuss for competitive reasons. (These are in addition to GILD’s two known HCV drug candidates: the non-nuke, GS9190, and the PI, GS9256.)

• Enrollment is “brisk” in GILD’s all-oral phase-2a trial of GS9256 + GS9190 with and without ribavirin. Preliminary data is expected in 2H10.

• GILD says they are still “assessing the data” to determine what to do with the GS91900+SoC program but, as previously noted, I don’t think this program is viable (#msg-46036072).

I'm assuming that GILD is not referring to ACH-1095 (ACHN's NS4A antagonist) under the first bulletpoint insofar as ACH-1095 has not formally entered Phase 1 trials as I understand and also because GILD hasn't formally opted back in to the developement of ACH-1095 with ACHN. (GILD is waiting on ACHN to demonstrate PoC with 1095 before even considering opting back in to the program.) Regardless, I still view ACH-1095 as the least consequential of ACHN's HCV programs, well behind ACH-1625 and ACH-2684. Management seems to view this as well based on the fact that much less time is typically spent discussing 1095 during calls compared to 1625 and 2684.